Dr. Jan zur Hausen Elected to the Supervisory Board of MagForce AG

BERLIN--(Marketwire - August 17, 2012) -

MagForce AG / MagForce AG: Dr. Jan zur Hausen elected to the Supervisory Board of MagForce AG . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.

* Renowned life sciences and investment banking expert strengthens the company's Supervisory Board

MagForce AG (Frankfurt, XETRA: MF6), a leading medical device company in the field of nanomedicine with focus on oncology, announced today that Dr. Jan zur Hausen was unanimously elected to the company's Supervisory Board at yesterday's Annual General Meeting. He is taking over from Dr. Stefan Elßer, who resigned effective as of the end of the Annual General Meeting.

Dr. Jan zur Hausen (born in 1965) is a managing shareholder of Bergmann zur Hausen & Cie. GmbH, a corporate finance company that evolved from Sal. Oppenheim's investment banking activities. While at Sal. Oppenheim, Dr. zur Hausen was responsible for numerous transactions in the life sciences area as Senior Vice President and Head of Healthcare.

Dr. zur Hausen has in-depth knowledge of health sciences and investment banking. He has a degree in biology, gained a Ph.D. in cell biology from the University of Basel, and previously worked at Hoffmann-La Roche, MPM Capital, Mulligan BioCapital, and DVC Deutsche Venture Capital, among others.

Dr. zur Hausen has known MagForce for many years now. "Dr. zur Hausen is an excellent addition to the Supervisory Board thanks to his many years' experience in the areas of both life sciences and investment banking. We see his election as offering strong support for our current corporate strategy," commented Dr. Andreas Jordan, Executive Board of MagForce AG. "We are convinced that his expertise will enable him to provide us with important advice as we continue on our path and we would like to thank Dr. Elßer, who worked dedicatedly for MagForce for many years, for resigning from the Supervisory Board and making this step possible."

"I am looking forward to the challenges at MagForce AG and to my new tasks," said Dr. Jan zur Hausen following his election. "MagForce is going through a difficult period at the moment, but it is on the right track. I hope that I will be able to make a positive contribution to the company's future development."

About MagForce AG

MagForce AG is a leading medical technology company in the field of nanomedicine in oncology. The Company's proprietary NanoTherm® therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of magnetic nanoparticles. NanoTherm®, NanoPlan®, and NanoActivator™ are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of MagForce AG in selected countries. For more information, please visit www.magforce.com.

Disclaimer

This release may contain forward-looking statements and information that may be identified by formulations using terms such as "expects", "aims", "anticipates", "intends", "plans", "believes", "seeks", "estimates", or "will". Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may differ substantially from these forward-looking statements. MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments differing from those anticipated.

MagForce_Press Release_Jan zur Hausen_Aug 17, 2012: http://hugin.info/143761/R/1634696/524958.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: MagForce AG via Thomson Reuters ONE [HUG#1634696]